Absci Investor Presentation Deck

CASE STUDY: DE NOVO DESIGN IN SILICO 'Zero-shot' designs of new antibodies from scratch using generative Al ● Zero-Shot: Model has never seen a binder to target or homologs • Binders were identified straight out of the model - no lead optimization was performed • Predicted structures reveal meaningful biological interactions • Demonstrated across four therapeutic targets: HER2, VEGF-A, COVID omicron, undisclosed target ABSCI CORPORATION 2023 ALL RIGHTS RESERVED HER2 ANTIGEN HEAVY CHAIN HCDR3 LIGHT CHAIN TRASTUZUMAB IMGT RESI106 SIDE CHAIN TRASTUZUMAB IMGT RESI107 SIDE CHAIN TRASTUZUMAB IMGT RESI109 SIDE CHAIN TRASTUZUMAB IMGT RESI113 SIDE CHAIN TRASTUZUMAB IMGT RESI117 SIDE CHAIN TRASTUZUMAB HCDR3S BACKBONE DE NOVO HCDR3S BACKBONES absci. 17

View entire presentation